BioSpace News Archive

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced an agreement with a biopharmaceutical company to validate its FREEDOM™ Infusion System for use with the biopharma company’s drug, a novel biologic.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company will participate in the Canaccord Genuity 43rd Growth Conference, which takes place August 7 – 10, 2023 in Boston, Massachusetts.

Mettler-Toledo International Inc. announced second quarter results for 2023. Provided below are the highlights: Reported sales were flat compared with the prior-year.

Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS) today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market.

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update.

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, announced that it is commencing an underwritten public offering of $60,000,000 of shares of its common stock.

ImmunoGen, Inc. announced that the Company will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston, MA.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.

Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”) today announced that, in its pivotal Phase 3 “PHOENIX” trial for subjects with GA, the first subject has been dosed at the Retina Associates of Southern California, a clinical trial site in the United States.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the hiring of Craig A. Dais, CPA in the position of Chief Financial Officer (CFO), reporting directly to the Company’s Chief Medical Officer.